DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model

Cancer Immunology, Immunotherapy

Volumn 61, Issue 10, 2012, Pages 1857-1867

  Zhang, Haihong ^a   Wang, Yuqian ^a   Liu, Chenlu ^a   Zhang, Lixing ^a   Xia, Qiu ^a   Zhang, Yong ^a   Wu, Jiaxin ^a   Jiang, Chunlai ^a   Chen, Yan ^a   Wu, Yongge ^a   Zha, Xiao ^b   Yu, Xianghui ^a   Kong, Wei ^a  

^a JILIN UNIVERSITY   (China)

^b SICHUAN CANCER HOSPITAL   (China)

Author keywords

Chemotherapeutics; Immunoadjuvant; Prime boost; Survivin; Tumor vaccine

Indexed keywords

ADENOVIRUS VECTOR; CANCER VACCINE; CARBOPLATIN; DNA VACCINE; INTERLEUKIN 2; SURVIVIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER INHIBITION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DNA IMMUNIZATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; EMBRYO; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; MELANOMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR IMMUNITY; TUMOR REJECTION; VIRUS RECOMBINANT;

ADENOVIRIDAE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CARBOPLATIN; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INTERLEUKIN-2; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MUTATION; SKIN NEOPLASMS; TREATMENT OUTCOME; VACCINES, DNA;

EID: 84867575801     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1296-3     Document Type: Article

References (42)

1. Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69-90
2. Bolhassani A, Safaiyan S, Rafati S (2011) Improvement of different vaccine delivery systems for cancer therapy. Mol Cancer 10:3
3. Altieri DC (2008) Survivin, cancer networks and pathwaydirected drug discovery. Nat Rev Cancer 8:61-70
4. Ishizaki H, Manuel ER, Song G-Y et al (2010) Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model. Cancer Immunol Immunother 60:99-109
5. Kim HS, Kim CH, Park MY et al (2010) Efficient co-transduction of adenoviral vectors encoding carcinoembryonic antigen and survivin into dendritic cells by the CAR-TAT adaptor molecule enhance anti-tumor immunity in a murine colorectal cancer model. Immunol Lett 131:73-80
6. Lladser A, Ljungberg K, Tufvesson H et al (2009) Intradermal DNA electroporation induces survivin-specific CTLs, suppresses angiogenesis and confers protection against mouse melanoma. Cancer Immunol Immunother 59:81-92
7. Zwirner NW, Domaica CI (2010) Cytokine regulation of natural killer cell effector functions. BioFactors 36:274-288
8. Decker WK, Qiu J, Farhangfar F et al (2006) A retrogen plasmidbased vaccine generates high titer antibody responses against the autologous cancer antigen survivin and demonstrates anti-tumor efficacy. Cancer Lett 237:45-55
9. Lladser A, Parraga M, Quevedo L et al (2006) Naked DNA immunization as an approach to target the generic tumor antigen survivin induces humoral and cellular immune responses in mice. Immunobiology 211:11-27
10. Zhu K, Qin H, Cha SC et al (2007) Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models. Vaccine 25:7955-7961
11. Barouch DH, Nabel GJ (2005) Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum Gene Ther 16:149-156
12. Schulte R, Suh YS, Sauermann U et al (2009) Mucosal prior to systemic application of recombinant adenovirus boosting is more immunogenic than systemic application twice but confers similar protection against SIV-challenge in DNA vaccine-primed macaques. Virology 383:300-309
13. Andersen MH, Sorensen RB, Schrama D et al (2008) Cancer treatment: the combination of vaccination with other therapies. Cancer Immunol Immunother 57:1735-1743
14. Yu B, Zhang Y, Zhan Y et al (2011) Co-expression of herpes simplex virus thymidine kinase and Escherichia coli nitroreductase by an hTERT-driven adenovirus vector in breast cancer cells results in additive anti-tumor effects. Oncol Rep 26:255-264
15. Herrmann M, Lorenz HM, Voll R et al (1994) A rapid and simple method for the isolation of apoptotic DNA fragments. Nucleic Acids Res 22:5506-5507
16. Nagaraj S, Pisarev V, Kinarsky L et al (2007) Dendritic cellbased full-length survivin vaccine in treatment of experimental tumors. J Immunother 30:169-179
17. Zhang S, Zhang H, Shi H et al (2008) Induction of immune response and anti-tumor activities in mice with a DNA vaccine encoding human mucin 1 variable-number tandem repeats. Hum Immunol 69:250-258
18. Li F, Ackermann EJ, Bennett CF et al (1999) Pleiotropic celldivision defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1:461-466
19. Grossman D, McNiff JM, Li F, Altieri DC (1999) Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 113:1076-1081
20. Grossman D, McNiff JM, Li F, Altieri DC (1999) Expression of the apoptosis inhibitor, survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line. Lab Invest 79:1121- 1126
21. O'Connor DS, Grossman D, Plescia J et al (2000) Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci USA 97:13103-13107
22. O'Connor DS (2000) Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Nat Acad Sci 97:13103-13107
23. Grossman D, Kim PJ, Schechner JS, Altieri DC (2001) Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci USA 98:635-640
24. Yagihashi A, Ohmura T, Asanuma K et al (2005) Detectio n of autoantibodies to survivin and livin in sera from patients with breast cancer. Clin Chim Acta 362:125-130
25. Kameshima H, Tsuruma T, Torigoe T et al (2011) Immunogenic enhancement and clinical effect by type-I interferon of antiapoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients. Cancer Sci 102:1181-1187
26. Miyazaki A, Kobayashi J, Torigoe T et al (2011) Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer. Cancer Sci 102:324-329
27. Honma I, Kitamura H, Torigoe T et al (2009) Phase I clinical study of anti-Apoptosis protein survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancer. Cancer Immunol Immunother 58:1801-1807
28. Tsuruma T, Torigoe T, Hata F et al (2004) Anti-Apoptosis protein, survivin-2B-derived peptide vaccine therapy. Gan To Kagaku Ryoho 31:1634-1636
29. Tsuruma T, Hata F, Torigoe T et al (2004) Phase I clinical study of anti-Apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med 2:19
30. Trepiakas R, Berntsen A, Hadrup SR et al (2010) Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial. Cytotherapy 12:721-734
31. Hirschowitz EA, Foody T, Hidalgo GE, Yannelli JR (2007) Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells. Lung Cancer 57:365-372
32. Pisarev V, Yu B, Salup R et al (2003) Full-length dominantnegative survivin for cancer immunotherapy. Clin Cancer Res 9:6523-6533
33. Fuessel S, Meye A, Schmitz M et al (2006) Vaccination of hormone- refractory prostate cancer patients with peptide cocktailloaded dendritic cells: results of a phase I clinical trial. Prostate 66:811-821
34. Xiang R, Mizutani N, Luo Y et al (2005) A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res 65:553-561
35. Verdecia MA, Huang H, Dutil E et al (2000) Structure of the human anti-Apoptotic protein survivin reveals a dimeric arrangement. Nat Struct Biol 7:602-608
36. Chantalat L, Skoufias DA, Kleman JP et al (2000) Crystal structure of human survivin reveals a bow tie-shaped dimer with two unusual alpha-helical extensions. Mol Cell 6:183-189
37. Shi Y (2000) Survivin structure: crystal unclear. Nat Struct Biol 7:620-623
38. Bachinsky MM, Guillen DE, Patel SR et al (2005) Mapping and binding analysis of peptides derived from the tumor-Associated antigen survivin for eight HLA alleles. Cancer Immunol 5:6
39. Andersen MH, Pedersen LO, Becker JC, Straten PT (2001) Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res 61:869-872
40. Andersen MH, Pedersen LO, Capeller B et al (2001) Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res 61:5964-5968
41. Pitisuttithum P, Rerks-Ngarm S, Bussaratid V et al (2011) Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand. PLoS ONE 6:e27837
42. Gabrilovich DI (2007) Combination of chemotherapy and immunotherapy for cancer: a paradigm revisited. Lancet Oncol 8:2-3